Our findings indicated that stage I–II GC patients with an extremely low expression of LINC01094 (tumor/normal tissue expression fold <0.11) might not need postoperative adjuvant chemotherapy, which means that LINC01094 has a potential guiding value for clinical GC treatment, and LINC01094 is worthy of future large-sample-size studies to verify its clinical value. Here, LINC01094 is linked to gastric cancer.